Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583676 | 0.78 | — | — | |
| SCHEMBL7206662 | 0.69 | ADRA2A (0.68) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL6976306 | 0.68 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7206665 | 0.67 | ADRA2A (0.32) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL7659924 | 0.65 | PARP10 (0.39) | — | |
| SCHEMBL4624962 | 0.62 | DRD2 (0.37) | — | |
| SCHEMBL8644587 | 0.62 | HTR2C (0.38) | — | |
| SCHEMBL30664964 | 0.62 | HTR2A (0.38) | — | |
| SCHEMBL7657136 | 0.62 | HTR2A (0.38) | — | |
| Hydrochloric Acid SCHEMBL8111500 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395764-B1 | NOSAL DECONGESTION, RESPIRATORY SYSTEM DISORDERS | THE PROCTER & GAMBLE COMPANY | 2002-05-28 | — | — | US | claimed |
| CN-1238771-A | 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists | PROCTER & GAMBLE (US) | 1999-12-15 | — | — | CN | claimed |
| EP-0944621-A1 | 2-IMIDAZOLINYLAMINOINDOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998023610-A1 | 2-IMIDAZOLINYLAMINOINDOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| US-6610720-B2 | Administering to the patient an alpha-2 adrenoreceptor agonist for the treatment or prevention of emesis | MERCK FROSST CANADA & CO. (CA) | 2003-08-26 | — | — | US | disclosed |
| US-6395764-B1 | NOSAL DECONGESTION, RESPIRATORY SYSTEM DISORDERS | THE PROCTER & GAMBLE COMPANY | 2002-05-28 | — | — | US | disclosed |
| US-20020045565-A1 | Method for treating or preventing emesis | MERCK FROSST CANADA LTD. (CA) | 2002-04-18 | — | — | US | disclosed |
| US-6162818-A | 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists | THE PROCTER & GAMBLE COMPANY (US) | 2000-12-19 | — | — | US | disclosed |
| EP-0944621-A1 | 2-IMIDAZOLINYLAMINOINDOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023610-A1 | 2-IMIDAZOLINYLAMINOINDOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045565-A1 | Method for treating or preventing emesis | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885ADRA2B 4/4885ADRA2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.